Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the ... - Stock Titan
Longboard Pharmaceuticals announced positive interim results from the PACIFIC Study OLE, showing a 57.7% median reduction in countable motor seizures over ~9 months for bexicaserin in DEEs, with sustained efficacy and a favorable safety profile. The company plans to initiate a global Phase 3 program later this year.
Highlighted Terms
Related News
Bexicaserin showed a 57.7% reduction in countable motor seizures over 9 months, with favorable safety and tolerability. Data will be presented at the 15th European Epilepsy Congress. Full 12-month data expected early next year.
Longboard Pharmaceuticals reports bexicaserin achieved a 57.7% median seizure reduction in DEEs over 9 months, with favorable safety and tolerability. Data to be presented at the 15th European Epilepsy Congress. Full 12-month OLE dataset expected early next year.
Longboard Pharmaceuticals announced positive interim results from the PACIFIC Study OLE, showing a 57.7% median reduction in countable motor seizures over ~9 months for bexicaserin in DEEs, with sustained efficacy and a favorable safety profile. The company plans to initiate a global Phase 3 program later this year.
Longboard Pharmaceuticals reports interim results from 52-week open-label extension of Phase II PACIFIC Study, showing a median 57.7% decrease in countable motor seizure frequency across 40 participants with developmental and epileptic encephalopathies (DEEs). The study also noted high retention rate (92.7%) and favorable safety and tolerability profile.
Longboard Pharmaceuticals reported interim results from its 52-week open-label extension of the Phase II PACIFIC Study, showing a median 57.7% decrease in countable motor seizure frequency across 40 participants with developmental and epileptic encephalopathies (DEEs). The study assessed bexicaserin's safety, tolerability, and impact on seizure frequency, with consistent results regardless of initial treatment. A high retention rate of 92.7% was noted, and the company plans to provide a full analysis with 12-month data next year.
Bexicaserin showed a 57.7% median seizure reduction in DEEs over 9 months, with favorable safety and tolerability. Data to be presented at the 15th European Epilepsy Congress in Rome, Italy. Full 12-month OLE dataset expected early next year.